Arrhythmias & electrophysiology

Atrial fibrillation (AF) ablation using a novel “single-shot” map-and-ablate spherical array pulsed field ablation catheter: 1-Year outcomes of the first-in-human PULSE-EU trial

Heart RhythmPublished First-in-human single-arm trial

Authors' conclusion

The single-shot spherical array PFA catheter can safely achieve durable lesions, translating into good clinical efficacy.

Study context

Population
Patients with AF (paroxysmal 48%, persistent 52%)
Participants
48 patients
Outcome
Acute PV isolation (PVI), PVI durability and atrial arrhythmia recurrence (primary and secondary efficacy end points)

Main finding

As reported in the abstract

Acute PVI

Pulmonary veins (PVs) acutely isolated

187 of 187 PVs

100%

Secondary outcomes

PV isolation (PVI) durability at invasive remapping · ∼3 months

PVs durably isolated
158 of 169 PVs (93.5%)
  • Remapping in 43/48 patients [89.5%]

Freedom from atrial arrhythmia (Kaplan-Meier estimate) · 1 year

Paroxysmal AF
84.2%
Persistent AF
80.0%

Acute lesion success, posterior wall and mitral isthmus

Posterior walls
20 of 20 posterior walls (100%)
Mitral isthmuses
10 of 11 mitral isthmuses (91%)

Safety

Only complication: drug-responsive pericarditis
1

Original publication

AF ablation using a novel “single-shot” map-and-ablate spherical array pulsed field ablation catheter: 1-Year outcomes of the first-in-human PULSE-EU trial. Heart Rhythm. Published 18 May 2024. doi:10.1016/j.hrthm.2024.04.102

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.